AbbVie Inc. (ABBV) Quarterly Net Income
The quarterly net income for AbbVie Inc. (ABBV) is $699.00M with a period-over-period change of (61.51%). Quarterly net income is profit after expenses, taxes, interest, and other items for the latest fiscal quarter.
ABBV Quarterly Net Income Chart
Quarterly Net Income History
| Date | Quarterly Net Income | % Change |
|---|---|---|
| Q1 2026 | $699.00M | (61.51%) |
| Q4 2025 | $1.82B | +876.34% |
| Q3 2025 | $186.00M | (80.17%) |
| Q2 2025 | $938.00M | (27.06%) |
| Q1 2025 | $1.29B | +5945.45% |
| Q4 2024 | ($22.00M) | (101.41%) |
| Q3 2024 | $1.56B | +13.94% |
| Q2 2024 | $1.37B | +0.07% |
| Q1 2024 | $1.37B | +66.55% |
| Q4 2023 | $822.00M | (53.77%) |
| Q3 2023 | $1.78B | (12.15%) |
| Q2 2023 | $2.02B | +746.86% |
| Q1 2023 | $239.00M | (90.34%) |
| Q4 2022 | $2.47B | (37.38%) |
| Q3 2022 | $3.95B | +327.38% |
| Q2 2022 | $924.00M | (79.42%) |
| Q1 2022 | $4.49B | +11.03% |
| Q4 2021 | $4.04B | +27.21% |
| Q3 2021 | $3.18B | +315.01% |
| Q2 2021 | $766.00M | (78.44%) |
| Q1 2021 | $3.55B | +9769.44% |
| Q4 2020 | $36.00M | (98.44%) |
| Q3 2020 | $2.31B | +412.74% |
| Q2 2020 | ($738.00M) | (124.52%) |
| Q1 2020 | $3.01B | +7.46% |
| Q4 2019 | $2.80B | +48.67% |
| Q3 2019 | $1.88B | +154.25% |
| Q2 2019 | $741.00M | (69.83%) |
| Q1 2019 | $2.46B | +234.50% |
| Q4 2018 | ($1.83B) | (166.47%) |
| Q3 2018 | $2.75B | +38.53% |
| Q2 2018 | $1.98B | (28.75%) |
| Q1 2018 | $2.78B | +5251.92% |
| Q4 2017 | $52.00M | (96.81%) |
| Q3 2017 | $1.63B | (14.83%) |
| Q2 2017 | $1.92B | +11.92% |
| Q1 2017 | $1.71B | +23.01% |
| Q4 2016 | $1.39B | (12.95%) |
| Q3 2016 | $1.60B | (0.75%) |
| Q2 2016 | $1.61B | +18.91% |
| Q1 2016 | $1.35B | (10.74%) |
| Q4 2015 | $1.52B | +22.44% |
| Q3 2015 | $1.24B | (9.30%) |
| Q2 2015 | $1.37B | +33.66% |
| Q1 2015 | $1.02B | +226.17% |
| Q4 2014 | ($810.00M) | (260.08%) |
| Q3 2014 | $506.00M | (53.92%) |
| Q2 2014 | $1.10B | +12.04% |
| Q1 2014 | $980.00M | (13.12%) |
| Q4 2013 | $1.13B | +17.01% |
| Q3 2013 | $964.00M | (9.74%) |
| Q2 2013 | $1.07B | +10.33% |
| Q1 2013 | $968.00M | (37.13%) |
| Q4 2012 | $1.54B | (2.86%) |
| Q3 2012 | $1.58B | +25.10% |
| Q2 2012 | $1.27B | +43.49% |
| Q1 2012 | $883.00M | (23.72%) |
| Q4 2011 | $1.16B | +9284.38% |
| Q3 2011 | $12.34M | (99.20%) |
| Q2 2011 | $1.54B | +112.95% |
| Q1 2011 | $723.20M | - |
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Michael